InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningfagfællebedømt

Standard

InforMing the PAthway of COPD Treatment (The IMPACT Study) : Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. / Singh, D.; Criner, G. J.; Dransfield, M. T.; Halpin, D. M. G.; Han, M. K.; Jones, C. E.; Kilbride, S.; Lange, P.; Lomas, D. A.; Martinez, F. J.; Pascoe, S. J.; Wise, R. A.; Lipson, D. A.

I: American Journal of Respiratory and Critical Care Medicine, Bind 199, Nr. A1116 , A24, 2019.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningfagfællebedømt

Harvard

Singh, D, Criner, GJ, Dransfield, MT, Halpin, DMG, Han, MK, Jones, CE, Kilbride, S, Lange, P, Lomas, DA, Martinez, FJ, Pascoe, SJ, Wise, RA & Lipson, DA 2019, 'InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use', American Journal of Respiratory and Critical Care Medicine, bind 199, nr. A1116 , A24. <https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1116>

APA

Singh, D., Criner, G. J., Dransfield, M. T., Halpin, D. M. G., Han, M. K., Jones, C. E., Kilbride, S., Lange, P., Lomas, D. A., Martinez, F. J., Pascoe, S. J., Wise, R. A., & Lipson, D. A. (2019). InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. American Journal of Respiratory and Critical Care Medicine, 199(A1116 ), [A24]. https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A1116

Vancouver

Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE o.a. InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. American Journal of Respiratory and Critical Care Medicine. 2019;199(A1116 ). A24.

Author

Singh, D. ; Criner, G. J. ; Dransfield, M. T. ; Halpin, D. M. G. ; Han, M. K. ; Jones, C. E. ; Kilbride, S. ; Lange, P. ; Lomas, D. A. ; Martinez, F. J. ; Pascoe, S. J. ; Wise, R. A. ; Lipson, D. A. / InforMing the PAthway of COPD Treatment (The IMPACT Study) : Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use. I: American Journal of Respiratory and Critical Care Medicine. 2019 ; Bind 199, Nr. A1116 .

Bibtex

@article{35010ec1ca7c46e9aa2249f691332e0a,
title = "InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use",
author = "D. Singh and Criner, {G. J.} and Dransfield, {M. T.} and Halpin, {D. M. G.} and Han, {M. K.} and Jones, {C. E.} and S. Kilbride and P. Lange and Lomas, {D. A.} and Martinez, {F. J.} and Pascoe, {S. J.} and Wise, {R. A.} and Lipson, {D. A.}",
year = "2019",
language = "English",
volume = "199",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "A1116 ",

}

RIS

TY - ABST

T1 - InforMing the PAthway of COPD Treatment (The IMPACT Study)

T2 - Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use

AU - Singh, D.

AU - Criner, G. J.

AU - Dransfield, M. T.

AU - Halpin, D. M. G.

AU - Han, M. K.

AU - Jones, C. E.

AU - Kilbride, S.

AU - Lange, P.

AU - Lomas, D. A.

AU - Martinez, F. J.

AU - Pascoe, S. J.

AU - Wise, R. A.

AU - Lipson, D. A.

PY - 2019

Y1 - 2019

M3 - Conference abstract in journal

VL - 199

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - A1116

M1 - A24

ER -

ID: 218435775